ExLibris header image
SFX Logo
Title: The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels
Source:

Pharmacogenomics Journal [1470-269X] Kerb, R yr:2001


Collapse list of basic services Basic
Full text
Full text available via Nature
GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. "CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment." Pharmacogenomics and personalized medicine. 11: 51-58. Link to SFX for this item
2. Thatte, Urmila M. "Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients." Neurology India 60.6 (2012): 577-580. Link to Full Text for this item Link to SFX for this item
3. Neuman, M G G. "A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes." Clinical biochemistry 33.7 (2000): 517-24. Link to Full Text for this item Link to SFX for this item
4. Hoffmeyer, S. "Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo." Proceedings of the National Academy of Sciences of the United States of America 97.7 (2000): 3473-8. Link to Full Text for this item Link to SFX for this item
5. Boniface, Franklin N. "Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma." Cancer 104.4 (2005): 682-91. Link to Full Text for this item Link to SFX for this item
6. Gennis, M A A. "Familial occurrence of hypersensitivity to phenytoin." The American journal of medicine 91.6 (1991): 631-4. Link to Full Text for this item Link to SFX for this item
7. "Long-Stay Mood Stabilizer Use Increasing as Prescription of Antipsychotics Decreases." GeroPsych. 36.1: 42-47. Link to SFX for this item
8. "FGF12 p.Gly112Ser variant as a cause of phenytoin/phenobarbital responsive epilepsy." Clinical genetics. 96.3: 274-275. Link to SFX for this item
9. Su, S. "Cardiotoxin-III selectively enhances activation-induced apoptosis of human CD8+ T lymphocytes." Toxicology and applied pharmacology 193.1 (2003): 97-105. Link to SFX for this item
10. Neuman, Manuela G. "Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs." Translational Research 159.5 (2012): 397-406. Link to SFX for this item
11. Stewart, A.. "Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration." Clinical cancer research 6.11 (2000): 4186-4191. Link to SFX for this item
12. Rieder, M. "Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides." The journal of pharmacology and experimental therapeutics 244.2 (1988): 724-8. Link to SFX for this item
13. SHEAR, D M H. "Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity." Annals of Internal Medicine 105.2 (1986): 179-84. Link to SFX for this item
14. Abraham, J. "A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine." Clinical cancer research (2009): 3574-3582. Link to SFX for this item
15. Tabatabaei, A R R. "A rapid in vitro assay for evaluation of metabolism-dependent cytotoxicity of antiepileptic drugs on isolated human lymphocytes." Fundamental and applied toxicology 37.2 (1997): 181-189. Link to SFX for this item
16. Sergieva, S B B. "99mTc-MIBI scintigraphy as a functional method for the evaluation of multidrug resistance in breast cancer patients." Journal of BUON 11.1 (2006): 61-8. Link to SFX for this item
17. Dieras. "Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies." Clinical cancer research 11.17 (2005): 6256-6260. Link to SFX for this item
18. Labrie, P. "In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2)." Bioorganic & medicinal chemistry 15.11 (2007): 3854-3868. Link to SFX for this item
19. Bebawy, M. "Differential pharmacological regulation of drug efflux and pharmacoresistant schizophrenia." BioEssays 30.2 (2008): 183-8. Link to Full Text for this item Link to SFX for this item
20. Elsinga, Philip H H. "PET studies on P-glycoprotein function in the blood-brain barrier: How it affects uptake and binding of drugs within the CNS." Current pharmaceutical design 10.13 (2004): 1493-1503. Link to SFX for this item
View More...
View Less...
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.